Ibogaine thread (biggest one-shot PTSD cure, but **making it safe** is imperative)

#1

[important to have this thread bc sudden death is possible, and people with trauma can be desperate to finally try]. One-shotting trauma or PTSD can be huge.
(also it’s the one Republicans tend to be least opposed to)

from a source: it really changed Rick Perry.

So like, you can get it 20 miles south of Tijuana or in Costa Rica
So someone told me a magnesium IV can prevent most of the cardiac risk. I’ll fact-check this later.

HOWEVER, it doesn’t heal everyone [for one person it didn’t cause them the standard life review that happened with others]
eg one person reported they replayed their traumatic memories and then completely forgot those memories, denying they ever happened [and this cured their PTSD/trauma] - which sounds VERY steve ramirez-ish

1 Like
#2

supporting evidence please?

#3

“No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury,” Williams said. “The results are dramatic, and we intend to study this compound further.”

A recent open-label study of the psychedelic ibogaine, coupled with magnesium to protect against cardiotoxicity, also showed significant improvements in PTSD after a single session in combat-exposed veterans with traumatic brain injury (Cherian et al., 2024).

2 Likes
#4

If someone is going to use ibogaine at all, the Stanford/MISTIC-style logic is: oral ibogaine + IV magnesium + continuous ECG + medically trained staff + exclusions.
Not “IV ibogaine.” The ibogaine in the Stanford-linked veteran study was oral; the magnesium sulfate was given intravenously, with continuous 5-lead ECG/QTc monitoring and ACLS-capable staff onsite. Tiny distinction, only the heart cares. :anatomical_heart::zap:

Why magnesium matters

Ibogaine’s scary failure mode is not primarily “bad trip.” It is cardiac repolarization delay, meaning QT/QTc prolongation, which can tip into torsades de pointes, ventricular tachycardia/fibrillation, and cardiac arrest.

Mechanistically, ibogaine and noribogaine can interfere with hERG potassium channels, which are crucial for resetting the heart’s electrical cycle. Reviews and case reports consistently flag QT prolongation and malignant ventricular arrhythmias as the major safety concern. A 2026 review notes these events have occurred even at therapeutic doses and even in people without known pre-existing cardiac disease.

Magnesium is relevant because IV magnesium is a standard emergency treatment for torsades-like physiology and can reduce arrhythmia risk even when QT is prolonged. The Stanford/Nature Medicine paper says magnesium may mitigate ibogaine’s cardiac risk and notes prior evidence that magnesium can reduce QT interval or protect against QT-prolonging medications.

Why IV magnesium, not just “take magnesium pills”?

Because the danger window is acute and electrophysiological. Oral magnesium is slow, variable, GI-limited, and can cause diarrhea, which is exactly the sort of electrolyte-chaos joke the universe tells right before an arrhythmia.

IV magnesium gives predictable blood levels quickly. That matters if QTc is drifting upward during the ibogaine/noribogaine exposure window. In one ibogaine detoxification safety study, 8 subjects received magnesium infusions because QT prolongation exceeded 500 ms on ECG monitoring.

So the point is not “magnesium is a wellness supplement.” The point is acute anti-arrhythmic risk control.

Why monitoring matters as much as magnesium

Magnesium is not a force field. Ibogaine risk is a stack:

Risk layer Why it matters
QT prolongation Creates torsades/VT/VF risk
Noribogaine duration Active metabolite prolongs exposure
CYP2D6 variability Some people metabolize differently, so exposure can be weirdly high
Electrolytes Low K/Mg/Ca increases arrhythmia risk
Bradycardia Slow heart rate worsens torsades risk
Drug interactions SSRIs, antipsychotics, methadone, some antibiotics, antiemetics, stimulants, etc. can worsen QT or metabolism
Vomiting/dehydration Electrolyte shifts plus autonomic stress, because apparently the body needed more failure modes
Underlying heart/liver/kidney disease Raises exposure and lowers safety margin

The Stanford/MISTIC study did not just “add magnesium and hope.” It excluded people with cardiovascular, liver, kidney, psychotic-symptom, and acute-suicidal-behavior risks, and used onsite medical staff with advanced cardiovascular life support experience plus continuous ECG/QTc monitoring.

That is the actual safety package.

Why “just oral ibogaine at a retreat” is not comparable

Because oral ibogaine can still produce dangerous QT prolongation. A 2024 case report described multiple cardiac arrests after a single low dose in a person without structural heart disease.

So the honest hierarchy is:

  1. No ibogaine: safest.
  2. Clinical trial / hospital-grade protocol: least insane if pursuing it.
  3. MISTIC-like medical clinic with IV magnesium, continuous ECG, electrolytes, ACLS staff, emergency transfer capacity: still risky, but recognizably medical.
  4. Retreat center with a nurse, a pulse ox, and incense: absolutely not enough.
  5. Solo / informal / home use: cardiac Darwinism with extra paperwork.

Does magnesium make it “truly safe”?

No. It makes it less stupid.

The Stanford veteran study found no serious or unexpected adverse events and reported large improvements in PTSD, depression, anxiety, and functioning at 1 month, but it was open-label, only 30 male special-operations veterans, and the authors explicitly said controlled trials are needed.

That matters because people online have converted “promising early signal in a carefully selected group” into “ibogaine heals trauma if you buy plane tickets.” Humanity, once again, has mistaken a pilot study for scripture. :scroll:

The core answer

IV magnesium is used because ibogaine’s main lethal risk is QT-driven arrhythmia, and IV magnesium is one of the few acute tools that can reduce torsades risk. But it only makes sense inside a broader protocol: baseline ECG, electrolytes, medication washout, exclusion criteria, continuous ECG/QTc monitoring, medical staff, and emergency response capability.

1 Like
#5

Worked for 10s

There is now a real human signal that magnesium + ibogaine can reduce MRI-predicted brain age, but there is no evidence yet that ibogaine reverses epigenetic age.

A 2026 Stanford-associated observational study followed Special Operations veterans with blast TBI after a magnesium-ibogaine protocol. One month later, their MRI-based predicted brain age fell by about 1.3 years on average. The study also found increased cortical thickness in 11 regions and expansion in several subcortical regions.

That sounds deliciously “anti-aging,” but the authors themselves put a large warning sticker on the interpretation. The brain-age measure was brainageR applied to T1 MRI, not a molecular aging clock. It means the post-treatment MRI looked somewhat more like MRI scans from younger people. It does not establish that neurons literally became biologically 1.3 years younger. The authors specifically caution against interpreting it that way.

The study also had only about 25 participants with usable baseline MRI, no untreated control group, all were unusually fit male veterans with multiple blast TBIs, and they received magnesium plus ibogaine, so you cannot cleanly attribute the effect to ibogaine alone. They also did not collect blood, saliva, or other biological samples that could have been used for molecular aging measurements.

What about epigenetic rejuvenation?

As far as the published literature I can find through August 2026, nobody has shown that ibogaine lowers an established DNA-methylation age clock such as:

Horvath / Skin&Blood

GrimAge

PhenoAge

DunedinPACE

brain-specific methylation-age clocks

So claims like “ibogaine reverses epigenetic age” are currently unsupported.

There is a mechanistic bridge that makes the hypothesis interesting. In rodents, a single ibogaine exposure produces substantial changes in transcription of BDNF, GDNF and NGF in dopamine-related regions, with some effects persisting after the drug itself has largely cleared. For example, GDNF expression increased strongly in VTA/SN at higher experimental doses, while BDNF transcription changed across PFC, NAcc, VTA and SN.

But:

changed gene expression ≠ rejuvenated epigenome.

You could imagine something like:

ibogaine → receptor/signaling perturbation → transcription-factor activity → chromatin remodeling → altered neurotrophin expression → synaptic/structural plasticity → MRI looks “younger.”

That entire causal chain is plausible. Only pieces of it have actually been demonstrated.

The intriguing Janusian interpretation is that ibogaine may make a brain look younger without making its molecular clock younger. MRI brain age is sensitive to cortical thickness, tissue composition, hydration, inflammation, myelination and other relatively plastic features. DNA-methylation clocks capture a rather different slice of biological aging. Those two clocks can move independently.

So my confidence ladder would be:

Ibogaine induces durable molecular/neuroplastic changes: fairly good animal evidence.
Ibogaine changes human brain structure/function: emerging evidence.
Magnesium-ibogaine reduces MRI-predicted brain age: one interesting human study.
Ibogaine reverses cellular/epigenetic aging: unknown.
Ibogaine is a longevity intervention: nowhere near established.

The 2026 result is nevertheless much more interesting than I would have said a year ago. It gives an actual experimentally measurable “brain-age” signal rather than just psychedelic-neuroplasticity rhetoric.

#6

https://www.sciencedirect.com/science/article/pii/S2589004226004967

Wow it increased brain size

#7

Rick Perry literally called it senolytic that improved his executive function and made his brain younger

Rick Perry reduced his brain atrophy by 25 percent

#8

Don’t believe advertorials on YouTube…

and Rick Perry has a history of saying some ridiculous things:

Rick Perry (2011): The Presidential Debate “Oops” Memory Collapse

  • The Comment: During a televised Republican primary debate, Governor Perry declared his intention to dismantle the federal bureaucracy: “It’s three agencies of government when I get there that are gone: Commerce, Education, and the… what’s the third one there? Let’s see… The third agency of government I would—I would do away with, Education, the… Commerce and, let’s see. I can’t. The third. I’m sorry. Oops.”
  • The Accurate Truth: The third agency Perry intended to name was the United States Department of Energy—the Cabinet department responsible for managing the nation’s nuclear weapons arsenal, naval nuclear reactors, and national laboratory complex. In 2017, Perry was appointed and confirmed to lead that exact department as Secretary of Energy.

Rick Perry (2011): Claiming Galileo was “Outvoted” to Dismiss Scientific Consensus

  • The Comment: Challenged during a debate on his rejection of anthropogenic climate change research, Perry defended his position by arguing that scientific consensus is historically flawed: “Galileo got outvoted for a spell.”
  • The Accurate Truth: Perry inverted the history of science. Galileo Galilei was not outvoted by a democratic consensus of empirical scientists. He was prosecuted, convicted of vehement suspicion of heresy, and sentenced to lifelong house arrest by the Roman Catholic Inquisition in 1633

I. Video Executive Summary

In the analyzed clip, political advocate Rick Perry posits that a single administration of the monoterpene indole alkaloid ibogaine can execute a systemic central nervous system “reset,” impart measurable “senolytic values,” reverse biological brain aging (“turning back the clock”), and augment executive function in healthy older adults (specifically referencing his own demographic as an asymptomatic 73-year-old male). The speaker asserts that when clinically dosed, diagnosed, and supervised, ibogaine operates as an effective geroprotective intervention.

From a clinical and molecular pharmacology perspective, these claims represent an unvalidated extrapolation of preliminary, open-label neuropsychiatric data into the domain of geroscience. The primary empirical foundation underlying public discourse regarding ibogaine’s cognitive effects stems from observational studies in specific clinical cohorts—predominantly combat veterans suffering from blast-induced mild traumatic brain injury (TBI), treatment-resistant post-traumatic stress disorder (PTSD), and major depressive disorder (MDD), as characterized by Cherian et al., 2024. In that open-label trial (n=30), adjunctive magnesium-ibogaine therapy demonstrated significant reductions in Clinician-Administered PTSD Scale scores and secondary improvements in processing speed and executive metrics. However, these cognitive gains reflect the remediation of severe trauma-induced neuroinflammation and psychiatric disability rather than an enhancement of normal baseline cognition or true biological rejuvenation in healthy, aging brain tissue.

Crucially, the assertion that ibogaine exhibits “senolytic values” is unsupported by empirical evidence. Ibogaine does not selectively induce apoptosis in p16INK4a- or p21CIP1-positive senescent cells, nor does it attenuate the senescence-associated secretory phenotype (SASP) via established senotherapeutic mechanisms (e.g., BCL-2/BCL-xL inhibition or PI3K/AKT pathway modulation). Its primary neurobiological effects are driven by complex multi-target receptor modulation (NMDA receptor antagonism, κ-opioid and μ-opioid receptor interactions, and σ2​ agonism) coupled with downstream upregulation of neurotrophic factors, most notably Glial Cell Line-Derived Neurotrophic Factor (GDNF) and Brain-Derived Neurotrophic Factor (BDNF).

Furthermore, ibogaine possesses an exceptionally narrow therapeutic index. It potently blocks human ether-à-go-go-related gene (hERG/Kv​11.1) potassium channels, inducing concentration-dependent QTc interval prolongation, severe bradycardia, and high-risk fatal ventricular tachyarrhythmias, specifically Torsades de Pointes (Litjens et al., 2022). Marketing this compound as an elective longevity or anti-aging therapeutic in healthy geriatric populations introduces life-threatening cardiotoxic hazards that vastly outweigh its unverified geroprotective claims.

II. Insight Bullets

Context, Origin & Translational Validity

  1. The video originates from a commercial medical tourism clinic channel (“Beond Ibogaine Treatment”) and features non-scientific political advocacy rather than clinical trial data.
  2. The primary speaker is an asymptomatic 73-year-old layman conflating clinical rehabilitation of traumatic brain injury with elective geriatric rejuvenation.
  3. The underlying clinical data referenced in contemporary public debates is derived from open-label pilot cohorts rather than Phase III randomized controlled trials (RCTs).
  4. No clinical trial to date has evaluated ibogaine administration in healthy, cognitively unimpaired older adults for longevity or cognitive enhancement.
  5. The claim of a single-treatment “brain reset” is a colloquial metaphor for multi-target receptor remodeling and transient neuroplasticity windows, not structural tissue replacement.

“Senolytic” & Biological Anti-Aging Claims

  1. There is zero published preclinical or clinical evidence demonstrating that ibogaine selectively eliminates senescent cells (senolysis).
  2. Ibogaine does not inhibit anti-apoptotic BCL-2 family proteins (BCL-2, BCL-xL, BCL-W), the canonical target of validated senolytic compounds.
  3. The alkaloid has not demonstrated modulation of the senescence-associated secretory phenotype (SASP), such as downregulating IL-6, IL-1β, or MMP-3.
  4. No human epigenetic clock data (e.g., Horvath DNAmAge, GrimAge, DunedinPACE) has been published evaluating ibogaine-induced systemic or neural age deceleration.
  5. Conflating neuroplastic dendritic sprouting with “senolytic clearance” represents a fundamental biological category error.
  6. Age-related cognitive decline involves microglial priming, vascular stiffness, and mitochondrial DNA damage, none of which have demonstrated reversal under controlled ibogaine exposure.

Executive Function & Neurocognitive Evidence

  1. Demonstrated executive function improvements are strictly documented in populations recovering from blast-induced TBI, complex polytrauma, and severe substance use disorders.
  2. Executive recovery in TBI cohorts is confounded by massive concomitant reductions in PTSD, anxiety, and depressive symptomatology, which are known to severely suppress baseline executive performance.
  3. There is no evidence indicating that ibogaine acts as a nootropic or enhances executive performance beyond baseline in cognitively healthy individuals.
  4. Measured gains in executive function in clinical cohorts may reflect the resolution of trauma-induced functional disconnection rather than de novo cognitive enhancement.
  5. Uncontrolled setting outcomes are subject to substantial expectancy bias, halo effects, and placebo responses driven by intense oneirogenic/psychedelic experiences.

Pharmacodynamics & Receptor Affinity

  1. Ibogaine and its primary hepatic active metabolite, noribogaine, exhibit complex polypharmacology across multiple central nervous system receptors.
  2. Ibogaine acts as a low-affinity, non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor complex, modulating glutamatergic excitotoxicity.
  3. The compound exhibits partial agonist/antagonist activity at κ-opioid (KOR) and μ-opioid (MOR) receptors, facilitating substance withdrawal suppression.
  4. Ibogaine functions as an antagonist at α3​β4​ and α7​ nicotinic acetylcholine receptors (nAChR), altering autonomic and reward pathways.
  5. High-affinity binding to σ2​ receptors is observed, which has been linked to intracellular calcium signaling and potential neurotoxic thresholds at elevated dosages.
  6. Noribogaine acts as a potent serotonin reuptake inhibitor (SRI), introducing severe serotonin toxicity risks when combined with serotonergic pharmaceuticals.

Neurotrophic Factor Upregulation & Plasticity

  1. Preclinical models indicate that ibogaine significantly upregulates Glial Cell Line-Derived Neurotrophic Factor (GDNF) transcription in the ventral tegmental area (VTA) and substantia nigra.
  2. GDNF upregulation promotes the sprouting of dopaminergic neurites and provides cytoprotective signaling to vulnerable mesolimbic circuitry.
  3. Brain-Derived Neurotrophic Factor (BDNF) synthesis and subsequent TrkB activation are moderately increased downstream of ibogaine-mediated signaling cascades.
  4. Ibogaine induces rapid synaptogenesis and structural spinogenesis, mirroring mechanisms observed with other non-classical psychoplastogens.
  5. The enhanced neuroplastic window following treatment is temporary, necessitating intensive psychotherapeutic integration to retain behavioral adaptations.

Cardiotoxicity & Electrophysiological Hazards

  1. Ibogaine exhibits high-affinity blockade of the cardiac voltage-gated potassium channel hERG/Kv​11.1 (rapid delayed rectifier current IKr​).
  2. hERG blockade produces marked, concentration-dependent prolongation of the ventricular repolarization phase (QTc interval).
  3. In human clinical pharmacokinetic studies, over 50% of subjects treated with ibogaine developed a QTc interval exceeding 500 ms.
  4. A QTc prolongation exceeding 500 ms substantially elevates the immediate risk of fatal polymorphic ventricular tachycardia, specifically Torsades de Pointes (TdP).
  5. Fatalities associated with ibogaine administration occur primarily secondary to sudden cardiac arrest and fatal ventricular arrhythmias.
  6. Co-administration of intravenous or oral magnesium sulfate is utilized off-label to stabilize cardiomyocyte membrane resting potentials and shorten repolarization, though it does not eliminate hERG inhibition.
  7. Ibogaine triggers central and peripheral bradycardia, exacerbating early afterdepolarizations (EADs) and increasing arrhythmogenic vulnerability.
  8. The risk of cardiotoxicity is severely compounded in geriatric patients due to age-related conduction system fibrosis, subclinical coronary artery disease, and occult channelopathies.

Pharmacokinetics & Metabolism

  1. Ibogaine undergoes rapid first-pass hepatic O-demethylation via cytochrome P450 2D6 (CYP2D6) into noribogaine.
  2. CYP2D6 genetic polymorphism (poor vs. ultra-rapid metabolizers) creates extreme, unpredictable variations in systemic clearance and drug exposure.
  3. Poor CYP2D6 metabolizers retain parent ibogaine for extended durations, drastically increasing the duration of peak cardiotoxicity.
  4. Noribogaine possesses an elimination half-life (t1/2​) spanning 24 to 48+ hours, maintaining residual QTc prolongation well past the acute psychoactive window.
  5. Ibogaine is highly lipophilic and deposits into adipose tissue, leading to erratic redistributed elimination curves in individuals with variable body mass indexes.

Neurotoxicological & Other Organ System Risks

  1. High-dose preclinical rodent studies document localized neurotoxicity characterized by Purkinje cell degeneration in the cerebellum.
  2. Cerebellar Purkinje damage manifests clinically as severe, transient ataxia, motor tremors, and balance disturbances during the acute phase.
  3. Severe nausea, intractable emesis, and aspiration risks are prevalent during the oneirogenic state, requiring active airway monitoring.
  4. Psychomimetic effects include intense auditory/visual dream states, autonomic destabilization, and psychological distress that can destabilize psychiatric comorbidities.

Regulatory, Commercial, and Translational Realities

  1. Ibogaine remains classified as a Schedule I controlled substance in the United States, defined as having no approved medical application and high abuse liability.
  2. Medical tourism clinics operate outside FDA, EMA, or standard GCP regulatory oversight, creating significant heterogeneity in compound purity, dosing precision, and resuscitation preparedness.
  3. Commercial marketing framing ibogaine as a general “wellness,” “executive optimization,” or “anti-aging” compound constitutes predatory and unevidenced monetization.
  4. Non-hallucinogenic, non-cardiotoxic synthetic analogs (such as tabernanthalog / TBG) are currently in preclinical and early Phase I development to bypass hERG liability while preserving neuroplasticity.
  5. The presence of psychiatric and cognitive improvement in damaged brains cannot be extrapolated to indicate longevity extension in undamaged biological systems.
  6. Rigorous, blinded, placebo-controlled Phase II/III clinical trials are entirely absent for any indication beyond substance use and TBI-related neuropsychiatric sequelae.

III. Adversarial Claims & Evidence Table

Claim from Video Speaker’s Stated/Implied Basis Scientific Reality (Current Clinical Data) Evidence Grade Verdict
“One treatment… can literally reset the brain.” Single-dose psychedelic/oneirogenic therapeutic intervention. Multi-target receptor modulation and temporary TrkB/GDNF-driven neuroplasticity allow synaptic reorganization; it is not a physical cellular reset. Demonstrated primarily in open-label cohorts with blast TBI (Cherian et al., 2024). Level C (Human Observational) Speculative(Metaphorical, not literal)
“Has literally some senolytic values, turning back the clock.” Informal biological aging terminology conflated with neurogenesis. Zero empirical evidence. Ibogaine does not selectively target or eliminate senescent cells via BCL-2/BCL-xL, p53/p21, or p16 pathways, nor does it suppress SASP biomarkers. [Source unverified in live search for senolytic activity]. Level E (Expert Opinion / Anecdote) Unsupported
“Anti-aging of the brain.” Conceptual biological rejuvenation. Neurogenesis and synaptogenesis observed in preclinical models (GDNF/BDNF) do not constitute a reversal of whole-organ biological aging, telomere attrition, or epigenetic age. Level D (Pre-clinical / Translational Gap) Unsupported
“Increased executive functions [in a healthy 73-year-old].” Extrapolation from veteran TBI/PTSD recovery studies to healthy aging. Cognitive gains (processing speed, executive control) are clinically observed solely as secondary improvements resulting from the treatment of underlying PTSD, depression, and mild TBI. No randomized trial supports nootropic gains in healthy older adults. Level C (Human Observational in TBI only) Unsupported
“Properly dosed, diagnosed, and guided… safe for healthy seniors.” Clinical supervision protocols in medical tourism facilities. Highly dangerous. Ibogaine potently blocks hERG/Kv​11.1 potassium channels, resulting in severe QTc prolongation (>500 ms) and risk of fatal Torsades de Pointes (Litjens et al., 2022). Older adults face compounded arrhythmogenic risks. Level B (Human Pharmacokinetic/Safety Trials) Safety Warning